|
|
 |
|
ALKS: Alkermes Inc - Stock News |
Enter Ticker:
|
|
| Nov 20, 2009 |
Alkermes Begins Phase 2 Clinical Study of ALKS 33 for the Treatment of Alcohol Dependence |
| Nov 18, 2009 |
Alkermes Reports Results from Phase 3 Clinical Study of Naltrexone |
| Nov 17, 2009 |
Alkermes (ALKS) NewsBite - ALKS Upgraded By Leerink Swann |
| Nov 17, 2009 |
ALKS: Begins Phase 2 Trial of ALKS 33 for Alcohol Dependence |
| Nov 17, 2009 |
Alkermes (ALKS) Upgrade Alert, Watch for 12.7% Technical Downtrend Reversal |
| Nov 17, 2009 |
Analyst Upgrades for November 17th |
| Nov 17, 2009 |
Alkermes Initiates Phase 2 Clinical Study of ALKS 33 for the Treatment of Alcohol Dependence |
| Nov 17, 2009 |
Conference Calls Today: 3:10-3:55 P.M. EDT |
| Nov 16, 2009 |
xtremepicks.com: www.Xtremepicks.Com: Xtremepicks Alerts November 16, 2009 : RFMD, NETL, ALKS and CTXS |
| Nov 16, 2009 |
ALKS: Positive Phase 3 Results for Naltrexone ER Injectable |
| Nov 16, 2009 |
Alkermes Announces Positive Results from Phase 3 Clinical Study of Naltrexone for Extended-Release Injectable Suspension for the Treatment of Opioid Dependence |
| Nov 13, 2009 |
Alkermes to Webcast Corporate Presentation at the Lazard Capital Markets Healthcare Conference |
| Nov 12, 2009 |
Stock research report available on Alkermes (NASDAQ:ALKS) from SmarTrend Analytics |
| Nov 11, 2009 |
BenchmarkJournal.com Issues Independent Review on PAET, AKAM, CERN,INFY, HGSI and ALKS |
| Nov 10, 2009 |
Alkermes' Corporate Presentation to be Webcast at the Lazard Capital Markets Healthcare Conference |
| |
| ZACKS COMMENTARY FOR ALKS |
| Nov 18, 2009 | Zacks Blog: Good News for Alkermes’ Pipeline | | Nov 10, 2009 | Zacks Equity Research: Report for ALKS | | Nov 09, 2009 | Zacks Blog: Alkermes Moves to Loss but Beats | | Oct 14, 2009 | Zacks Blog: Good News for Alkermes’ Pipeline | | Sep 11, 2009 | Zacks Blog: Amylin Collaborates with Biocon | | Aug 28, 2009 | Zacks Blog: Zacks Analyst Blog Highlights: Alkermes, Inc., Johnson & Johnson, AstraZeneca, Eli Lilly and Pfizer | | Aug 27, 2009 | Zacks Blog: Setback for Alkermes’ Pipeline | | Jul 24, 2009 | Zacks Blog: Diabetes Drug Gets an Edge | | Jul 21, 2009 | Zacks Blog: Amylin Gets Positive Results | | Jul 09, 2009 | Zacks Blog: Alkermes: NDA Not Enough | | Jun 19, 2009 | Zacks Blog: Aradigm’s Pipeline Undervalued | | Jun 08, 2009 | Zacks Blog: Zacks Analyst Blog Highlights: MannKind, Pfizer, Inc., Novo Nordisk, Eli Lilly and Alkermes Pharmaceuticals. |
|
|
Sponsored Links 
-0.25